0.47
+0.2238(+90.98%)
Currency In USD
| Previous Close | 0.25 |
| Open | 0.34 |
| Day High | 0.53 |
| Day Low | 0.26 |
| 52-Week High | 3 |
| 52-Week Low | 0.22 |
| Volume | 262.41M |
| Average Volume | 2.86M |
| Market Cap | 4.68M |
| PE | -0.52 |
| EPS | -0.87 |
| Moving Average 50 Days | 0.6 |
| Moving Average 200 Days | 0.85 |
| Change | 0.2 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $3.34 as of June 26, 2025 at a share price of $0.338. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $9.73 as of June 26, 2025 at a share price of $0.338.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batch
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
GlobeNewswire Inc.
Jun 17, 2025 12:00 PM GMT
GLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and r
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
End of Phase 2 Meeting has been Rescheduled for July 29th Meeting to Discuss Upcoming Clinical Development Plan and Protocol Designs Strategic Partnership Discussions Expected to Accelerate Following a Positive FDA Meeting GLEN ALLEN, Va., June 16,